Envista (NYSE:NVST) Receives Neutral Rating from Piper Sandler

Envista (NYSE:NVST)‘s stock had its “neutral” rating reaffirmed by research analysts at Piper Sandler in a research note issued to investors on Thursday,Benzinga reports. They presently have a $28.00 price target on the stock, up from their previous price target of $26.00. Piper Sandler’s price target suggests a potential upside of 0.26% from the stock’s current price.

NVST has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price objective on shares of Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Morgan Stanley raised their target price on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Evercore reiterated an “outperform” rating and issued a $33.00 price target on shares of Envista in a research note on Thursday, May 7th. Citigroup assumed coverage on shares of Envista in a research report on Wednesday, April 15th. They set a “neutral” rating and a $29.00 price target on the stock. Finally, Weiss Ratings downgraded shares of Envista from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $29.15.

Envista Stock Down 2.5%

Shares of NVST stock traded down $0.70 during trading hours on Thursday, hitting $27.93. 3,108,584 shares of the company were exchanged, compared to its average volume of 2,953,366. The company has a market capitalization of $4.54 billion, a PE ratio of 68.04, a PEG ratio of 1.58 and a beta of 0.86. The business has a 50 day moving average of $25.87 and a two-hundred day moving average of $25.99. Envista has a 52 week low of $18.77 and a 52 week high of $30.42. The company has a current ratio of 2.44, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. Envista had a return on equity of 7.11% and a net margin of 2.41%.The business had revenue of $730.50 million for the quarter, compared to analyst estimates of $716.11 million. During the same quarter last year, the firm earned $0.26 EPS. Envista’s revenue for the quarter was up 7.1% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Analysts anticipate that Envista will post 1.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its position in Envista by 16,711.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP boosted its stake in shares of Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Envista by 46.1% in the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the last quarter. IFP Advisors Inc increased its position in shares of Envista by 102.9% during the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after buying an additional 1,071 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares during the last quarter.

More Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Quarterly earnings exceeded expectations. Envista reported adjusted EPS of $0.41, up from $0.26 a year earlier and above the $0.33–$0.34 analyst consensus. Envista Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Revenue also beat estimates and grew year over year. Sales reached $730.5 million versus expectations of $716.1 million, representing 7.1% growth from the comparable period. Envista Q2 Earnings Snapshot
• Positive Sentiment: Full-year guidance was raised or reaffirmed above consensus. Envista forecast fiscal 2026 EPS of $1.50–$1.55, compared with the current analyst consensus of approximately $1.43, signaling management confidence in future earnings. Envista 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Management discussed the quarter and outlook on its earnings call. Investors are likely evaluating the call’s details on operating performance, demand trends and execution against the updated guidance. Envista Q2 2026 Earnings Call Transcript
• Negative Sentiment: Profitability remains relatively thin. Envista’s reported net margin was 2.41%, while its price-to-earnings ratio was approximately 69. Investors may be taking profits or demanding stronger improvement before assigning additional value despite the earnings beat.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.